Abstract

Recently, we and others have illustrated that extracellular vesicles (EVs) have the potential to support hematopoietic stem and progenitor cell (HSPC) expansion; however, the mechanism and processes responsible for the intercellular communication by EVs are still unknown. In the current study, we investigate whether primary human bone marrow derived mesenchymal stromal cells (BMSC) EVs isolated from two different origins, fetal (fEV) and adult (aEV) tissue, can increase the relative low number of HSPCs found in umbilical cord blood (UCB) and which EV-derived components are responsible for ex vivo HSPC expansion. Interestingly, aEVs and to a lesser extent fEVs, showed supportive ex vivo expansion capacity of UCB-HSPCs. Taking advantage of the two BMSC sources with different supportive effects, we analyzed the EV cargo and investigated how gene expression is modulated in HSPCs after incubation with aEVs and fEVs. Proteomics analyses of the protein cargo composition of the supportive aEV vs. the less-supportive fEV identified 90% of the Top100 exosome proteins present in the ExoCarta database. Gene Ontology (GO) analyses illustrated that the proteins overrepresented in aEVs were annotated to oxidation-reduction process, mitochondrial ATP synthesis coupled proton transport, or protein folding. In contrast, the proteins overrepresented in fEVs were annotated to extracellular matrix organization positive regulation of cell migration or transforming growth factor beta receptor (TGFBR) signaling pathway. Small RNA sequencing identified different molecular signatures between aEVs and fEVs. Interestingly, the microRNA cluster miR-99b/let-7e/miR-125a, previously identified to increase the number of HSPCs by targeting multiple pro-apoptotic genes, was highly and significantly enriched in aEVs. Although we identified significant differences in the supportive effects of aEVs and fEVs, RNAseq analyses of the 24 h treated HSPCs indicated that a limited set of genes was differentially regulated when compared to cells that were treated with cytokines only. Together, our study provides novel insights into the complex biological role of EVs and illustrates that aEVs and fEVs differentially support ex vivo expansion capacity of UCB-HSPCs. Together opening new means for the application of EVs in the discovery of therapeutics for more efficient ex vivo HSPC expansion.

Highlights

  • Allogeneic hematopoietic stem cell transplantation (HSCT) has become a common practice for the treatment of hematopoietic diseases (Copelan, 2006; Juric et al, 2016)

  • We investigated if the isolated bone marrow-derived mesenchymal stromal cells (BMSCs)-derived extracellular vesicles (EVs) were responsible for ex vivo expansion of umbilical cord blood (UCB)-CD34+ cells or whether other secreted factors were present in the EV-depleted supernatant or serum-free MSC medium

  • These results suggest the presence of supporting factors in the BMSC-derived EVs for the ex vivo expansion of UCB-CD34+ cells

Read more

Summary

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) has become a common practice for the treatment of (malignant-) hematopoietic diseases (Copelan, 2006; Juric et al, 2016). Most patients in need for HSCT do not have a suitable human leukocyte antigen (HLA)-matched related donor, and of these, less than half can find an HLA-matched unrelated donor (Gragert et al, 2014) For these patients, umbilical cord blood (UCB) has become an important hematopoietic stem and progenitor cell (HSPC) source for allogeneic HSCT. The relatively low number of HSPCs present in one UCB unit is a major limitation for UCB transplantation (de Lima et al, 2012; Kindwall-Keller and Ballen, 2020) This is associated with delayed engraftment and higher risk of graft failure, and leads to restriction in their widespread application (Mattsson et al, 2008). The development of efficient culture conditions and the discovery of new compounds that boost ex vivo HSPC expansion will help toward the treatment of malignant hematopoietic diseases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call